Keyuan Pharmaceutical was awarded the 2025 Forbes China Industry Development Innovation Brand Award.

       On March 22, the "2025 Forbes China Industry Development Trailblazers Selection" was held in Shanghai. Shandong Keyuan Pharmaceutical Co., Ltd. (abbreviated as "Keyuan Pharma"; Stock Code: 301281.SZ) won 2025 Forbes China Innovative Brands in Industry Development Award by outstanding innovation capabilities and industry influence. This award is not only a high recognition of Keyuan Pharma's intensive efforts in the field of chemical APIs and FDF, but also a testament to leapfrog development driven by innovation under the background of the adjustment of the global industrial landscape.

       This selection was jointly launched by Frost & Sullivan, aimed to identify outstanding enterprises and individuals in key fields such as new energy, AI technology, consumer goods, and biomedicine, who drive industry transformation with an innovative spirit. Keyuan Pharma's standing out this time demonstrates remarkable position in the biomedicine sector. 

         Since its establishment, Keyuan Pharma has been dedicated to the R&D, production, and sales of chemical APIs and FDF, established anti-diabetic, cardiovascular, and anesthetic products, and is a leading enterprise in the field of chemical drugs. In April 2023, Keyuan Pharma listed on the ChiNext of the Shenzhen Stock Exchange, further enhanced brand influence with the help of the capital market.

       Currently, Keyuan Pharma is promoting the acquisition of Hongjitang, planning to purchase 99.42% of its equity through the issuance of shares and cash payment. If this acquisition is successful, it will help Keyuan Pharma and Hongjitang give full play to their respective advantages and achieve the coordinated development of chemical drug and traditional Chinese patent medicine.

      Innovation is the core driving force for Keyuan's development. Keyuan continues to increase its R&D investment, explores cutting-edge technologies, and improves innovation system. Recently, Keyuan Pharma obtained the a utility model patent authorization for "A Preliminary Drying Device for Metformin HCl Processing Materials", which is the 4th patent authorization this year. A series of patent achievements have provided solid support for the improvement of product quality, production efficiency, and cost control, helping Keyuan gain an advantage in the fierce market competition.

       Looking ahead, taking this award as an opportunity, Keyuan will continue to uphold the concept of innovation, deepen R&D innovation, accelerate the integration with Hongjitang, continuously expand product line, increase market share, provide patients with more high-quality and efficient drugs, demonstrate the power of "Chinese innovation" in the global pharmaceutical market, and make greater contributions to the development of the enterprise and the progress of the industry.

       Article source: Shanghai Securities News · China Securities Network